Mental health care is fraught with treatment-resistant conditions and ineffective or side-effect-ridden therapies.1 Psychedelic therapy, once relegated to the fringes of medical
It’s no secret that 2023 has been a year for a shift in thinking when it comes to psychedelics, in particular as pertains to their use for hard-to-treat or treatment resistant mental health
In another example of consolidation in the digital therapeutics (DTx) category, Big Health has agreed to buy Limbix, adding its app for adolescents and young adults with s
The US FDA announced today that it has cleared two novel gene therapies for sickle cell disease: Vertex Pharmaceuticals' Casgevy and bluebird bio's Lyfgenia.
On 1st October, the roll-out of the National Contract Value Review (NCVR) process marked a pivotal moment in the trajectory of clinical research in the UK, introducing a standardised, natio